Vericel Corp.

Company Snapshot

Founded: 1989
Entity Type: Public
Employees: 314
Region: U.S.
Revenue: $197.5 Millions
Revenue Year: 2023
Headquarter: U.S.
Key Geographics: North America
Corporate Address: 64 Sidney Street Cambridge Massachusetts-02139 U.S. Tel. +1-(617)-588-5555 www.vcel.com

Company Overview

Vericel Corp. is a fully integrated, biopharmaceutical company known for its advanced therapies catering to the sports medicine and severe burn care sectors. Vericel currently markets Epicel and Maci, two advanced cell therapy products, in the U.S. The company uses proprietary cell-processing technology to expand naturally occurring populations of cells derived from the patient’s own tissue. The company’s cell-manufacturing facility is located in Massachusetts.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Vericel Corp. In Reports

Global Market for Cell and Gene Therapy

BCC Research Market Report provides an overview of Cell and Gene Therapy Market is segmented into rare diseases, oncology, hematology, cardiovascular, neurology and others based on application.

Global Market for Stem Cells

BCC Research Market Analysis Report says Stem Cells market has reached $32.1 billion in 2022 and should reach $65.6 billion by 2027 with a CAGR of 15.3%.

Global Cell and Gene Therapy Market

BCC Research Market Report for cell and gene therapy should grow from $4.1 billion in 2021 to $17.4 billion by 2026 with a compound annual growth rate (CAGR) of 33.6%

Company's Business Segments

  • Cell Therapy : The company manufcatures and markets advanced cell therapy products for sports medicine and severe burn care across the U.S..

Applications/End User Industries

  • Healthcare